Y-Biologics, a South Korean biotechnology company, and French pharmaceutical group Pierre Fabre have signed a license agreement granting Pierre Fabre rights globally exclusive to develop and commercialize a family of human antibodies generated through the Y-Biologics proprietary Y-Biologics phage display human antibody library Ymax-ABL.
Vivera's product pipeline includes oral medications and medications formulated in the TABMELT® sublingual drug delivery system. By bringing innovative new drugs to market through the clinical trial and commercial process, Vivera's clinical research partnership with Parexel will offer new medication management options to patients and health care providers.